Researchers have tested a novel therapeutic concept to treat virus-induced lung failure in patients with severe COVID-19 in a phase 2 clinical trial. The approach may also be applicable to other ...

The grant will support Perspectum’s research into the development of a novel biomarker for primary sclerosing cholangitis ...

The U.S. Food and Drug Administration approved PTC Therapeutics, Inc.'s Kebilidi (eladocagene exuparvovec-tneq) gene therapy for the ...

The new rules, which cover both TV and radio, instruct drugmakers to use simple, consumer-friendly language when describing ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

Iambic, which has previously won investment from tech giant Nvidia (NVDA.O), opens new tab, published details of its new AI drug discovery model, named "Enchant". Enchant was trained on large ...

Hiddo L. Heerspink got the idea for this study at the beginning of the corona pandemic. Earlier, he had discovered that another class of drugs against type 2 diabetes, the so-called SGLT2 ...

A new study has examined a large sample of privately ... patients corresponding to the rising use of blockbuster GLP-1 RA drugs," said senior author Thomas C. Tsai, MD, MPH, a metabolic bariatric ...

Federal officials have celebrated a striking drop in drug overdoses across the country. But state-level data shows that Black people are suffering significantly worse outcomes than white people.

the lead author of a new study that looked at health records of 17 million privately insured Americans with obesity. It found that between 2022 and 2023, as prescriptions for GLP-1 drugs more than ...

Semaglutide medications — such as Ozempic, the popular diabetes drug — have been linked to a reduced risk of Alzheimer’s disease for certain groups. A new study, which was led by researchers ...

Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options Vandana Singh Thu, Oct 24, 2024, 12:42 PM 2 min read ...